Navigating Digitalization, QRM Maturity, and Global Compliance Convergence into 2026

Navigating Digitalization, QRM Maturity, and Global Compliance Convergence into 2026

PharmTech connected recently with Henrik Johanning, senior vice president, Quality & Strategy, Epista Life Science, to look back at 2025 and ahead into 2026. Johanning details major European regulatory and manufacturing trends transitioning from 2025 into 2026, focusing on the operationalization of modern quality risk management (QRM) and tangible upgrades required for facilities to achieve…

Read More
The Top 10 PharmTech Videos of 2025

The Top 10 PharmTech Videos of 2025

A look back at the top 10 PharmTech videos of 2025 reveals several overarching themes dominating the pharmaceutical industry landscape, primarily centered on advancing complex therapeutic modalities, navigating stringent regulatory environments, and accelerating development through technological integration. A significant focus across these videos was on specialized medicines, including gene therapies using adeno-associated virus (AAV) vectors,…

Read More
The Year of the Tariff: Pharmaceutical Supply Chain Reimagined in 2025

The Year of the Tariff: Pharmaceutical Supply Chain Reimagined in 2025

The year 2025 was defined by escalating global trade tensions that fundamentally reshaped the pharmaceutical supply chain, forcing major companies to commit billions to domestic manufacturing to avoid crippling import tariffs (Infographic – article continues below). What was the immediate aftershock, and what major investment pledges followed? The year opened with immediate policy shifts targeting…

Read More
The Truth About Wegovy: Convenience Isn’t Enough –

The Truth About Wegovy: Convenience Isn’t Enough –

An oral formulation of Wegovy may facilitate initiation of treatment for some patients, particularly those who dislike injections. However, the primary reason most patients stop GLP-1 therapy is not the delivery method — it’s the side effects. Nausea, GI issues, and overall tolerability remain the most significant barriers to long-term adherence. A pill may improve…

Read More
Fish Oil vs Algae Oil in 2025: Sustainability, Absorption, Bioavailability, and Vegan Considerations

Fish Oil vs Algae Oil in 2025: Sustainability, Absorption, Bioavailability, and Vegan Considerations

December 27, 2025 Table of Contents Understanding Omega-3 Fatty Acids: EPA, DHA, and ALA Why the Source of Omega-3 Matters? Fish Oil: Source, Composition, and Absorption Scientific Evidence and Clinical Understanding Algae Oil: Direct-from-Source Omega-3 Sustainability of Fish Oil and Algae Oil in 2025 Safety, Purity, and Quality Control Clinical Evidence: Established vs Emerging Research…

Read More
Zero-Tolerance to Falsified Medicines: How MVS Pharma GmbH Ensures Full EU GDP Compliance

Zero-Tolerance to Falsified Medicines: How MVS Pharma GmbH Ensures Full EU GDP Compliance

December 27, 2025 Table of Contents EU GDP Expectations for Prevention of Falsified Medicines MVS Pharma’s Risk-Based Approach to Falsified Medicines Prevention Controlled Handling of Suspected Falsified Medicines Continuous Awareness and Preventive Controls Conclusion The prevention of falsified medicines is a critical responsibility under the EU Good Distribution Practice (GDP) Guidelines. Falsified medicinal products pose…

Read More